Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Dermatomyositis, Polymyositis
Interventions
M5049 high dose, Placebo
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
13
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced May 22, 2026, 12:11 AM EDT
Conditions
Idiopathic Inflammatory Myositis
Interventions
Daxdilimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced May 22, 2026, 12:11 AM EDT
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions
ALLO-329, Cyclophosphamide
Genetic · Drug
Lead sponsor
Allogene Therapeutics
Industry
Eligibility
18 Years to 69 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
12
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced May 22, 2026, 12:11 AM EDT
Conditions
IBM, IIM, Myositis, Inflammatory Myopathy, Dermatomyositis, Dermatomyositis, Juvenile, Anti-synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Polymyositis, Inclusion Body Myositis, Juvenile Myositis, Juvenile Dermatomyositis
Interventions
No intervention - qualitative and mixed methods investigations
Other
Lead sponsor
Myositis International Health & Research Collaborative Alliance Foundation
Other
Eligibility
7 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced May 22, 2026, 12:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers
Conditions
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis, Juvenile Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
2 Years to 100 Years
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
8
States / cities
Miami, Florida • Baltimore, Maryland • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 22, 2026, 12:11 AM EDT
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions
CNTY-101, IL-2, Lymphodepleting Chemotherapy
Biological · Drug
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
17 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 22, 2026, 12:11 AM EDT
Conditions
Myositis, Interstitial Lung Disease
Interventions
Abatacept, Placebo
Drug · Other
Lead sponsor
Rohit Aggarwal, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced May 22, 2026, 12:11 AM EDT
Conditions
Idiopathic Inflammatory Myopathies
Interventions
Rapcabtagene autoleucel, Active Comparator Option
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
8
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 22, 2026, 12:11 AM EDT
Conditions
Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis
Interventions
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Biological
Lead sponsor
Cabaletta Bio
Industry
Eligibility
6 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
31
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 12:11 AM EDT